DELRAY BEACH, Fla., Sept. 8, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Active Wound Care Market is projected to reach USD 4.50 billion by 2031 from USD 3.19 billion in 2026, at a CAGR of 7.1% during the forecast period.
Browse 250 market data Tables and 150 Figures spread through 350 Pages and in-depth TOC on "Active Wound Care Market - Global Forecast to 2031"
Active Wound Care Market Size & Forecast:
- Market Size Available for Years: 2026–2031
- 2026 Market Size: USD 3.19 billion
- 2031 Projected Market Size: USD 4.50 billion
- CAGR (2026–2031): 7.1%
Active Wound Care Market Trends & Insights:
- North America accounted for the largest regional market share of 44.9% in 2025, supported by high chronic-wound burden, established wound-care infrastructure, reimbursement availability for selected advanced products, and the presence of leading manufacturers.
- Biological skin substitutes accounted for the largest share of 56.8% in 2025, supported by the established use of human donor tissue-derived and animal-derived regenerative products.
- Chronic wounds accounted for the largest share in 2025 because of the sustained burden of diabetic foot ulcers, venous leg ulcers, and pressure injuries.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=259878425
Growth is driven by the increasing prevalence of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure injuries; the rising incidence of diabetes and peripheral vascular disorders; and the growing clinical adoption of regenerative and tissue-repair technologies. Increasing utilization of biological and synthetic skin substitutes, placental and extracellular matrix-based products, and growth factor-based therapies is also supporting market expansion. Greater emphasis on reducing wound-healing time, preventing amputations and other complications, and improving outcomes in difficult-to-heal wounds is further strengthening demand across hospitals, wound care centers, specialty clinics, and ambulatory settings.
Biological skin substitutes accounted for the largest share of the global active wound care market, by product type, in 2025.
Based on product type, the active wound care market is segmented into biological skin substitutes; biosynthetic/synthetic skin substitutes; topical agents, including growth factor- and cytokine-based agents and others; and other active wound care products, including collagen-based products. In 2025, biological skin substitutes accounted for the largest share, supported by their increasing use in chronic and complex wounds, growing clinical evidence supporting tissue regeneration, and the availability of a broad range of human donor tissue-derived and animal-derived products. Biological skin substitutes provide extracellular matrix structures and, depending on the product, viable cellular or biologically active components that support tissue repair and wound closure. Their increasing utilization in diabetic foot ulcers, venous leg ulcers, pressure injuries, surgical wounds, burns, and other difficult-to-heal wounds continues to support the segment's leading market position.
Chronic wounds accounted for the largest share of the active wound care market, by wound type, in 2025.
Based on wound type, the market is segmented into chronic wounds and acute wounds. In 2025, chronic wounds accounted for the largest share, primarily due to their prolonged treatment duration, high recurrence rates, and increasing prevalence among aging and diabetic populations. Rising cases of diabetic foot ulcers, venous insufficiency, pressure injuries, peripheral vascular disease, and associated wound-healing complications are increasing demand for regenerative and biologically active wound care products.
Hospitals accounted for the largest share of the active wound care market, by end user, in 2025.
Based on end user, the market is segmented into hospitals; wound care centers and specialty clinics, including burn centers and trauma centers; ambulatory surgical centers; home healthcare settings; and other end users. In 2025, hospitals accounted for the largest share because they play a central role in managing severe and complex chronic wounds, surgical and dehisced wounds, burns, traumatic injuries, and patients requiring multidisciplinary wound care. Hospitals also perform a substantial number of debridement, reconstructive, grafting, and other surgical procedures in which advanced wound matrices and tissue substitutes may be used. Availability of wound care specialists, surgeons, multidisciplinary clinical teams, and access to advanced treatment technologies further supports the segment's dominant position.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=259878425
North America accounted for the largest regional share of the global active wound care market in 2025.
The active wound care market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America accounted for the largest share, supported by the high prevalence of diabetes and chronic wounds, established wound care infrastructure, widespread availability of advanced regenerative products, and the strong presence of leading active wound care manufacturers. The region also benefits from a well-developed network of hospitals, outpatient wound care centers, podiatry practices, and specialty clinics, along with comparatively greater adoption of cellular and tissue-based products and other advanced wound-healing technologies.
Key Players
Leading players in the Active Wound Care companies include Smith+Nephew plc (UK), Organogenesis Holdings Inc. (US), MIMEDX Group, Inc. (US), Integra LifeSciences Holdings Corporation (US), Coloplast A/S (Denmark), ConvaTec Group plc (UK), Solventum Corporation (US), AROA Biosurgery Limited (New Zealand), PolyNovo Limited (Australia), AVITA Medical, Inc. (US), Stryker Corporation (US), Tissue Regenix Group plc (UK), URGO Group (France), and Anika Therapeutics, Inc. (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=259878425
Active Wound Care Market - Investment & funding +Merger & Acquisition
Investment Funding Context
Investment activity in the active wound care ecosystem remains substantial but has become more selective, with capital concentrating on differentiated regenerative technologies, clinically supported biological products, synthetic and biosynthetic tissue matrices, scalable manufacturing platforms, and products that can expand beyond reimbursement-dependent chronic-wound settings into burns, trauma, and complex surgical wounds. The scale of strategic capital committed to the sector is demonstrated by Coloplast's acquisition of Kerecis for up to USD 1.3 billion in 2023, including USD 1.2 billion upfront. The transaction provided Coloplast entry into the high-growth US biologics wound care market through Kerecis' intact fish-skin regenerative technology.
Strategic funding has continued to favor companies with differentiated platforms and opportunities to diversify into acute and surgical wound care. In December 2025, Solventum completed its acquisition of Acera Surgical after agreeing to pay USD 725 million in cash plus up to USD 125 million in contingent payments. Acera adds fully engineered synthetic tissue matrices based on electrospinning technology and gives Solventum greater exposure to regenerative tissue matrices in acute-care settings. In July 2026, MIMEDX agreed to acquire Sanara MedTech at an enterprise value of approximately USD 350 million; MIMEDX obtained a committed USD 300 million term loan from Hayfin Capital Management to finance the cash component alongside cash on hand.
Growth-stage wound care companies are also accessing debt and non-dilutive funding to expand commercialization, manufacturing capacity, and clinical evidence. AVITA Medical secured a five-year credit facility of up to USD 60 million from Perceptive Advisors in January 2026, with USD 50 million funded initially, to refinance existing debt and support further growth of its acute wound care portfolio. MIMEDX had earlier established USD 95 million of senior secured credit facilities in 2024 to strengthen its capital structure, while PolyNovo reported an additional USD 10 million of BARDA funding supporting its pivotal NovoSorb BTM full-thickness burn trial.
At the same time, the investment environment has become more sensitive to clinical evidence, product differentiation, reimbursement durability, manufacturing economics, and care-setting diversification. CMS fundamentally changed US Medicare payment for skin substitutes beginning in 2026, replacing the previous product-specific model with payment as incident-to supplies and establishing a single payment rate of approximately USD 127.28 for 2026 across the identified regulatory categories. CMS expects the change to substantially reduce Medicare spending on these products. This change increases investor emphasis on companies with evidence-supported products, efficient manufacturing, broader hospital and surgical exposure, and less reliance on historical physician-office reimbursement spreads.
Revenue Shift Context
The active wound care market is shifting from a revenue model heavily influenced by high-value physician-office skin-substitute reimbursement toward a more diversified mix of regenerative products across chronic wounds, hospital-based acute wounds, burns, trauma, and complex surgical applications. The 2026 Medicare payment reform is accelerating this transition by reducing the economic advantage previously associated with product-specific reimbursement and increasing the importance of clinical differentiation, appropriate patient selection, treatment economics, and evidence generation.